Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 515
Recruiting: 261
Ph III recruiting: 29
Growth YoY: +4.2%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 1–17 of 17 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07843940	A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)	not yet recruiting	Phase 1 / Phase 2	55	Boehringer IngelheimINDUSTRY	10	Sep 28, 2026	clinicaltrials
NCT07707895	DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers	not yet recruiting	Phase 1 / Phase 2	60	Boehringer IngelheimINDUSTRY	11	Sep 21, 2026